Articles

Cell-Mediated Immunity to Cancer

Cell-mediated immunity to cancer principally relies on the specificity of the interaction between T cells and tumor antigens presented by tumors and antigen-presenting cells (APC), although other types of cells may be the ultimate effectors. Many tumor antigens have been discovered in recent years. The immune system has been shown to recognize antigens that are shared between cancer and normal tissue, as well as those that are created by genetic alterations in the tumor.

Carbohydrate-Based Vaccines

Carbohydrate antoantigens have proven to be suitable targets for immune recognition and attack against cancer cells, because of their abundance at the cell surface and their unexpected immunogenicity.       
Carbohydrates play key roles in intracellular interactions as targets for selectins and adhesins, which may be crucial, not discretionary, to tumor cell survival and the metastatic process. Passively administered and vaccine-induced antibodies in preclinical models are capable of interfering with these processes directly, inducing complement-mediated inflammation and lysis and mediating opsonization, inflammation, and tumor cell death by other Fc-mediated mechanisms.

Cancer Vaccines: Peptideand Protein-Based Vaccines

Methods developed over the last several years have allowed tumor antigens that are recognized by MHC class I- and class II-restricted T cells to be readily identified. The screening of patient sera against tumor cell cDNA expression libraries has also resulted in the identification of a large number of antigens, some of which were also found to be recognized by tumor-reactive T cells. These antigens, as well as proteins that appear to be overexpressed in tumors, represent targets that can potentially be used for the development of cancer vaccines.      

Cancer Vaccines: Gene Therapy and Dendritic Cell-Based Vaccines

I. INTRODUCTION

Immunologists have long tried to exploit the immune system to control human disease, in many cases with great success. The prevention of viral diseases by immunizations that stimulate durable antibody responses is a cardinal example. Cancer and certain other infections have proven more elusive, however. Among the myriad reasons for this are that most tumor antigens (Ags) are self or differentiation Ags to which the immune system is not responsive, the tumor microenvironment itself may be inhibitory, and tumor cells lack the other surface molecules required for immunogenicity.  

Antibody-Toxin and Growth Factor-Toxin Fusion Proteins

The goal of cancer treatment is the elimination of tumor cells while inflicting the least amount of harm to normal cells. Because approximately half of all cancers are not cured using conventional therapies, new strategies are needed. One emerging therapeutic approach is the targeted delivery of highly toxic substances.

I. INTRODUCTION

Anti-idiotypic Antibody Vaccines

Anti-idiotypic antibodies bind to unique regions on other antibody molecules. One of the central hypotheses of modern immunology is that the immune system is regulated through a network of antibody-anti-idiotypic antibody interactions. One consequence of this theory is the idea that a specific B- or T-cell clone can be specifically activated by the appropriate anti-idiotypic antibody. In this way, antiidiotypic antibodies may be used as vaccines to induce active immunity against a foreign antigen.

Integrin-Targeted Angiostatics

Angiogenesis is the complex process by which new blood vessels grow. Like other tissues, the growth of tumors is dependent on the recruitment of a vascular bed, permitting the delivery of oxygen and nutrients while allowing the clearance of waste by-products. Endothelial cells in tumor-adjacent tissues are triggered by chemical signals from the tumor, causing them to become proliferative and eventually forming new sprouts into these areas.

Anti-Vascular Endothelial Growth Factor-Based Angiostatics

Physiological processes such as embryonic development, wound healing, and menstruation are known to require the formation of new blood vessels, angiogenesis, to meet increased needs for oxygen and nutrients. Pathological processes, such as cancer growth and chronic inflammatory diseases, also depend on angiogenesis. A number of different growth factors are implicated in angiogenesis and one of these, vascular endothelial growth factor (VEGF), is the focus of attention due to its critical and specific role in angiogenesis.